{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:25:54Z","timestamp":1750098354414},"reference-count":23,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.22014","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:15:59Z","timestamp":1664316959000},"page":"175-180","source":"Crossref","is-referenced-by-count":2,"title":["Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia"],"prefix":"10.3960","volume":"62","author":[{"given":"Anna","family":"Kawashiri","sequence":"first","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichiro","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Majhail NS, Tao L, Bredeson C et al.<\/i> Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013; 19: 1498-1501.","DOI":"10.1016\/j.bbmt.2013.07.020"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hasegawa W, Pond GR, Rifkind JT et al.<\/i> Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005; 35: 51-55.","DOI":"10.1038\/sj.bmt.1704706"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options Oncol. 2018; 19: 9.","DOI":"10.1007\/s11864-018-0528-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Deeg HJ, Soci\u00e9 G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998; 91: 1833-1844.","DOI":"10.1182\/blood.V91.6.1833"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Inamoto Y, Shah NN, Savani BN et al.<\/i> Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015; 50: 1013-1023.","DOI":"10.1038\/bmt.2015.63"},{"key":"6","unstructured":"6 Swerdlow SH. International Agency for Research on C: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, International Agency for Research on Cancer. 2017."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sorror ML, Maris MB, Storb R et al.<\/i> Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 2912-2919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ikegame K, Yoshida T, Yoshihara S et al.<\/i> Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: A Prospective Multicenter Phase I\/II Study in Japan. Biol Blood Marrow Transplant. 2015; 21: 1495-1505.","DOI":"10.1016\/j.bbmt.2015.04.012"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kurokawa T, Ishiyama K, Ozaki J et al.<\/i> Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol. 2010; 91: 661-669.","DOI":"10.1007\/s12185-010-0561-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Antin JH, Childs R, Filipovich AH et al.<\/i> Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 7: 473-485.","DOI":"10.1053\/bbmt.2001.v7.pm11669214"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hans CP, Weisenburger DD, Greiner TC et al.<\/i> Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Cheson BD, Fisher RI, Barrington SF et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Zhou Z, Sehn LH, Rademaker AW et al.<\/i> An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014; 123: 837-842.","DOI":"10.1182\/blood-2013-09-524108"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Dunleavy K, Pittaluga S, Maeda LS et al.<\/i> Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368: 1408-1416.","DOI":"10.1056\/NEJMoa1214561"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Miklos D, Cutler CS, Arora M et al.<\/i> Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017; 130: 2243-2250.","DOI":"10.1182\/blood-2017-07-793786"},{"key":"17","unstructured":"17 Hertenstein B, Hambach L, Bacigalupo A et al.<\/i> Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005; 90: 969-975."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Dietz AC, DeFor TE, Brunstein CG, Wagner JE Jr. Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response. Br J Haematol. 2014; 166: 209-212.","DOI":"10.1111\/bjh.12847"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kato M, Yamashita T, Suzuki R et al.<\/i> Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia. 2016; 30: 1742-1745.","DOI":"10.1038\/leu.2016.23"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Morscio J, Dierickx D, Ferreiro JF et al.<\/i> Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013; 13: 1305-1316.","DOI":"10.1111\/ajt.12196"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Djokic M, Le Beau MM, Swinnen LJ et al.<\/i> Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer. 2006; 45: 313-318.","DOI":"10.1002\/gcc.20287"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Schoch C, Schnittger S, Klaus M et al.<\/i> AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003; 102: 2395-2402.","DOI":"10.1182\/blood-2003-02-0434"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Meyer C, Burmeister T, Gr\u00f6ger D et al.<\/i> The MLL recombinome of acute leukemias in 2017. Leukemia. 2018; 32: 273-284.","DOI":"10.1038\/leu.2017.213"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22014\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T05:20:12Z","timestamp":1664601612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22014\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22014","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22014"}}